

Original Research Article

A STUDY OF SELECTIVE LASER TRABECULOPLASTY AS ADJUNCTIVE TREATMENT IN PATIENTS AFFECTED BY OPEN ANGLE GLAUCOMA FOR CONTROL OF INTRAOCULAR PRESSURE IN INDIAN EYES

ABSTRACT

Background – Prospective Interventional Pilot study of selective laser trabeculoplasty as adjunctive treatment in patients affected by open angle glaucoma for control of intraocular pressure in Indian eyes.

Methods- This prospective Interventional pilot study included 29 eyes of 29 patients affected by open angle glaucoma, were treated with Selective laser trabeculoplasty (360 degree trabecular meshwork treated with 100 spots)for IOP control between January 2011 to December 2011. Of these 29 patients, 24 were males, 5 were females. Mean age was 58.96 ± 18.19 years. Primary open Angle Glaucoma was diagnosed in 22 patients , Secondary Open Angle Glaucoma in 6, and Juvenile Open Angle Glaucoma in 1 patient. All patients underwent complete ophthalmic evaluation before SLT and at each follow up. This evaluation included visual acuity, IOP (GAT), slit lamp examination with 90D . The gonioscopy and visual field analysis was done at 6 &12 months. The IOP was measured on day 1, day 7 ,1 month,3 month,6 month and at 1 year post SLT On GAT.

Results-Main outcome measure was lowering of intraocular pressure on Goldmann Applanation Tonometry. The mean IOP Pre SLT (Selective Laser Trabeculoplasty) was 24.62 ± 6.38 , IOP was reduced to 14.20 ± 4.10 mmHg on Day 1 (42.32% reduction) , on day 7 it was 15.96 ± 4.731 mmHg (35.17% reduction), at 1 month it was 17.27 ± 4.77 mmHg(29.82% reduction), at 3 months it was 19.41 ± 4.40 mmHg(21.10% reduction), at 6 months it was 16.93 ± 4.03 mmHg(31.23% reduction) and at 1 year it was 16.47 ± 4.04 mmHg (31.3% reduction).After 3 months of follow up, 6 eyes out of 29 eyes, required Trabeculectomy with mitomycin C , for inadequate IOP control post SLT. These patients were considered as failures. In 2 patients topical medications decreased following SLT, remaining patients continued on same antiglaucoma medications. At follow up of 3 months 22 eyes(75.86%)out of 29 eyes maintained atleast 20% reduction from baseline IOP(Pre SLT IOP). At 6 months and 1 year of follow up 22 eyes out of 23 (95.65%),maintained atleast 20% reduction from baseline IOP (Pre SLT IOP). None of our patient had any complication or side effect following SLT.


Conclusion- Selective laser trabeculoplasty is effective and safe as a secondary/adjunctive treatment for lowering IOP in patients of open angle glaucoma not adequately controlled with medical therapy in Indian eyes.

SLT has good compliance and affordability.

Keyword :- laser treatment, Glaucoma, Trabeculoplasty, Intraocular Pressure

INTRODUCTION

37 Glaucoma is a slow progressive degeneration of the retinal ganglion cells (RGCs) and the optic nerve
 38 axons. Although increased intraocular pressure is a major risk factor of glaucoma, other factors
 39 include increased glutamate levels, alterations in nitric oxide (NO) metabolism, vascular alterations
 40 and oxidative damage caused by reactive oxygen species. Glaucoma is the second leading cause of
 41 blindness globally, accounting for 12.3% of the total blindness[1-3]. Glaucoma is a chronic
 42 progressive optic neuropathy that usually affects people over 40 years of age . It has characteristic
 43 visual field loss[1] and is often associated with high intraocular pressure. The pathogenesis of
 44 glaucoma progression is not completely known , but value of IOP is related to retinal ganglion cell
 45 loss. The IOP is maintained by constant balance between aqueous humor secretion from ciliary body
 46 and its drainage by trabecular meshwork (conventional is most common) and uveoscleral
 47 outflow.[2] In open angle glaucoma the IOP is increased due to increased resistance to aqueous
 48 humor outflow via trabecular meshwork. (figure 1 and 2)[2] Glaucoma is typically bilateral and
 49 causes progressive loss of peripheral vision leading to significant disability [Fig 1 and 2]. If unchecked
 50 patient continues losing vision leading to blindness[1-3].



51

52 **Figure 1 showing aqueous drainage in normal and in cases of open angle and closed angle**
 53 **glaucoma [2]**




Figure 2 Diagrammatic depiction of normal anatomy and ganglion cell damage associated with glaucomatous damage to optic nerve[2]

Glaucoma is second largest cause of blindness worldwide after cataract . WHO estimates that about 105 million people suffer from glaucoma around the world and an estimated 5.2 million are blind from it[2]. This is because there is no reliable and cost effective way of detecting and treating the disease in large population. The burden of blindness from different types of glaucoma is high[3-4] .

Glaucoma therapy plays important role in delaying the nerve fibre loss. Treatment at present can be pharmacological (drug therapy mainly topical), laser Trabeculoplasty[5,6], glaucoma filtration surgery. It plays an important role in lowering intraocular pressure (IOP). Also it is helpful in reducing the cost of treatment, noncompliance[7,8,9,10,11] .Patients have been found to miss one or the other topical medication. Reasons can be life style related, lack of awareness and financial condition. Glaucoma Filtration Surgical procedure is also associated with multiple complications like hypotony, bleb leak, shallow anterior chamber (AC), choroidal detachment [12] and long term complications like cataract and bleb related endophthalmitis[13] can be avoided. Also India is a developing country so need to have a cost effective treatment. Selective laser trabeculoplasty (SLT) is good treatment as it lowers IOP effectively and it has less complications and is very effective for lowering intraocular pressure. It is cost effective, avoids need of compliance[7,8,9,10,11] of the patient. SLT offers advantage that it uses selective wavelength which cause stimulation of only pigmented epithelium of trabecular meshwork , it does not distort the anatomy so it can be reused if required for lowering intraocular pressure(IOP), also it does not interfere with surgical outcome in future. We have included selective laser trabeculoplasty in our study as it has been proven to lower intraocular pressure effectively in Caucasian eyes but its data in Indian context is lacking.

79 RATIONALE OF THE STUDY

80 This study is important especially in Indian context as there is no such study using SLT in lowering
81 intraocular pressure in cases of open angle glaucoma not adequately controlled with medical
82 therapy done so far in India. SLT lowers intraocular pressure effectively, reduces cost of treatment
83 on patient, independent of compliance[7,8,9,10,11] (Both these factors are very important for
84 patients in developing country like India).

85 MATERIAL AND METHODS

86 Patients were recruited from glaucoma clinic of Advanced Eye Centre, Post Graduate Institute of
87 Medical Education and Research, spanning a period of one year from Jan 2011 to Dec 2011.
88 Informed consent was obtained from each patient after a complete description of the study. All
89 patients were subjected to a detailed ophthalmological examination including best corrected visual
90 acuity, contrast sensitivity, slit lamp examination of anterior segment, intraocular pressure
91 measurement by Goldmann Applanation tonometer, gonioscopy, detailed stereoscopic examination
92 of fundus with +90 diopter lens(Volk lens) and visual field testing programme 24-2/30-2 on
93 Humphrey Field analyser

94 (Humphrey® Field Analyzer /HFA™ II-i Series)

95 DESIGN:

96 Prospective Interventional Pilot study of selective laser trabeculoplasty as adjunctive treatment in
97 patients of open angle glaucoma for control of intraocular pressure

98 SELECTION CRITERIA:

99 INCLUSION CRITERIA

- 100 1. Age >18 years
- 101 2. Either sex
- 102 3. Primary open angle glaucoma
- 103 4. Pseudoexfoliation syndrome
- 104 5. Pigment dispersion syndrome
- 105 6. Patients ready to give consent for Selective Laser Trabeculoplasty
- 106 7. Patients available for follow-up up to at least 3 month

107 EXCLUSION CRITERIA

- 108 1. All glaucoma patients with co-existing ocular pathology such as media opacities, retina and
109 macular diseases
- 110 2. Patients who has undergone glaucoma surgery or laser iridotomy or ALT or LTP

3. Advanced visual field defects (scotoma within 10 degrees of fixation or split fixation on Humphrey visual field 24-2)

4. Angle closure glaucoma

Operative technique

The SLT device in clinical use is a 532-nm frequency-doubled, Q-switched Nd: YAG laser (SLT ELLEX LASER) with a 3 ns pulse and 400-µm beam diameter. After topical anesthesia, Latina SLT lens (Ocular Instruments Bellevue, WA) is used to focus a low-power laser aiming beam at the pigmented trabecular meshwork. The size of the treatment spot is 400µm. This is enough to cover the entire width of the trabecular meshwork, making accurate aiming less critical. We have increased the energy until small “champagne bubbles” are observed; it was then decreased by 0.1 mJ and treatment continued over 360 degree of trabecular meshwork. Approximately 100 spots applied to the full angle circumference. SLT treatment was continuous, confluent but non overlapping. After the procedure, patients continued to take their preoperative glaucoma medications until the IOP is re-evaluated till 3 months of study. Post op Non-steroidal or corticosteroid anti-inflammatory drops were not used.

POST SLT FOLLOW UP

We did not use any topical steroids or non-steroidal anti-inflammatory treatment given.

Patient were continued on previous antiglaucoma medication.

Ophthalmic examination were done at intervals of 1 day, 1 week , 1 month, 3 months, 6 months and at 1 year following SLT which included VA, IOP (on Goldmann Applanation Tonometry) and slit lamp examination.

RESULTS

Main outcome measure was lowering of intraocular pressure on Goldmann Applanation Tonometry. The mean IOP Pre SLT (Selective Laser Trabeculoplasty) was 23.78 ± 6.39 , IOP was reduced to 14.20 ± 4.10 mmHg on Day 1 (42.32% reduction) , on day 7 it was 15.96 ± 4.73 mmHg (35.17% reduction), at 1 month it was 17.27 ± 4.77 mmHg(29.82% reduction), at 3 months it was 19.41 ± 4.40 mmHg(21.10% reduction), at 6 months it was 16.93 ± 4.03 mmHg(31.23% reduction) and at 1 year it was 16.47 ± 4.04 mmHg (31.3% reduction).After 3 months of follow up, 6 eyes out of 29 eyes, required Trabeculectomy with mitomycin C , for inadequate IOP control post SLT. These patients were considered as failures. In 2 patients topical medications decreased following SLT, remaining patients continued on same antiglaucoma medications. At follow up of 3 months 22 eyes(75.86%)out of 29 eyes maintained at least 20% reduction from baseline IOP(Pre SLT IOP). At 6 months and 1 year of follow up 22 eyes out of 23 (95.65%),maintained atleast 20% reduction from baseline IOP (Pre SLT IOP). None of our patient had any complication or side effect following SLT.

DISCUSSION

Selective laser trabeculoplasty is a fast emergent technology in the management of open angle glaucoma. We wished to study its effectiveness and utility through our study in Indian eyes. In the present study, 29 eyes of 29 patients with open angle glaucoma were included.

Extent of Laser

We treated 360 degree of trabecular meshwork in single sitting. Various treatment protocols have been described in literature varying from 90 degree to 360 degree treatment.[26,49,51,53,58,59,60,62,67,71] . SLT have been shown to have better efficacy with 360 degree treatment. Study by Nagar et al [26] showed an IOP reduction of >20% in 34% of eyes treated with 90 degree , 65% with 180 degree and 82% with 360 degree SLT treatment. This suggest that 360 degree SLT treatment is associated with higher success rate. Therefore we choose to treat 360 degree trabecular meshwork in single sitting. Our patients had a mean baseline IOP of 23.78 ± 6.38 mmHg, after SLT it dropped to 19.00 ± 5.04 mmHg at 3 months follow up. This drop of >20% was seen in 54% of the treated eyes. Reported response rate with 360 degree SLT treatment varies from 24% to 82% [26,60] . Response rate of 54% in our population is lower than reported by Lai et al [70] in Chinese population and Nagar et al [26] in Caucasian population. This could be due to lower baseline IOP in our patients, as all of our patients were on anti glaucoma treatment. Hirn C. et al [62] did 360 degree trabecular meshwork SLT in patients who were on maximum tolerated medical therapy. They found significant reduction in mean IOP at 1 year . They noted IOP lowering of 5.6 mmHg which is similar to seen in present study.

Use of topical anti inflammatory agents

Post operatively we did not use any anti-inflammatory treatment. Currently there is no consensus on the use of steroidal or non steroidal anti-inflammatory agents. Steroids have been used to counter the in anterior segment inflammatory response in post SLT period. Proposed mechanism of SLT include "biologic theory"[30,73] that says Laser stimulating cellular activity. Following SLT, there is an increase in the recruitment and number of macrophages in the trabecular meshwork due to release of cytokine (IL1, TNF α) that cause remodelling of the extracellular matrix, allowing increased aqueous outflow from the eye [73]. It has been proposed that use of anti-inflammatory therapy might contribute to decrease in IOP lowering efficacy of SLT as proposed by Alvarado [74]. Therefore we did not use steroidal or non-steroidal anti-inflammatory treatment post-operatively as it can potentially decrease the efficacy of SLT.

Efficacy in open angle glaucoma subgroups

Published literature shows that IOP lowering similar in different form of OAGs (POAG, NTG, PXG, PG) [62,65,66]. In our patients, IOP lowering was similar in 3 subgroups of glaucoma [JOAG(22.67 ± 4.62), POAG(18.52 ± 5.42), and SOAG(19.29 ± 3.20)] at 1 year.

In our case series there was 1 case of JOAG which showed decrease in mean IOP compared from baseline at 1 year. Role of SLT in JOAG has not been reported earlier.

Published literature shows that IOP lowering similar in different form of OAGs (POAG, NTG, PXG, PG): Recent studies of using SLT in the treatment of NTG in an Asian population have shown that the amount of IOP-lowering is slightly less than in POAG probably due to the lower pre-treatment

186 IOP.[75-77] In our study there was no significant difference between open angle glaucoma
187 subgroups.

188 **Effect of nature and number of topical drugs**

189 IOP lowering efficacy is not affected by number of topical antiglaucoma medications. In present
190 study SLT was done in patients on maximum usable antiglaucoma medication for each patient. Most
191 of our patients were on 4 drugs (12 eyes) or 3 drugs (11 eyes). Patients who were on single drug
192 were on Prostaglandin. As reported by Hirn C. et al[62] demonstrating role of SLT in lowering IOP in
193 maximum tolerated medical therapy. So , SLT is effective in lowering IOP even in patients on
194 maximum tolerated medical therapy. Francis B. et al[58] reported that SLT is good as an adjunct to
195 medical therapy and reducing no. of topical antiglaucoma medication. Mc Ilraith et al[51] reported
196 SLT as initial and adjunctive to medical treatment. SLT not only lowers IOP in patients with different
197 number of topical antiglaucoma medication but also it can be used to decrease no. of topical
198 antiglaucoma medication and avoids need for additional antiglaucoma medication or need for
199 glaucoma filtration surgery.[26,51,58,62]

200 **ROLE OF AGE AND GENDER**

201 In our study efficacy of SLT is not affected by sex. Our study includes 24 males and 5 females. The
202 patients were enrolled between January 2011 to December 2011. There was so gender based
203 selection bias but the number of female eyes are too small to conclusively comment about the
204 response of SLT. Nevertheless our study showed a definite male predominance. The following study
205 also supports your findings that age and gender are not significant predictors of SLT success.[62,78]

206 **IOP LOWERING: EFFICACY OF SLT**

207 Mean reduction Of IOP achieved was 4.04 ± 1.01 mmHg(16.41% of baseline IOP) at 1 year in our
208 study. The reduction is comparable to other studies by Latina et al[49] (4.6 mmHg at 26 weeks) ,
209 Kajiya et al[55] (6.7 mmHg at 6 months), Hodge et al[65] (5.8 mmHg at 1 year), Damji et al[68] (4.8
210 mmHg at 6 months), Johnson et al [60](3.74 mmHg at 3 months), Jay Katz et al [71] (6.3 mmHg at
211 10 months), Hirn C. et al [62] (5.6mmHg at 11.97 months).

212 Detailed comparison of our study with previously reported studies is given in Table 1

213 **ADVERSE EVENTS**

214 **1.Anterior Chamber Inflammation**

215 In the initial study of 180 degrees SLT by Latina and coworkers [49], 83% of SLT-treated eyes
216 exhibited mild-to-moderate inflammation, appearing within 1 hour after treatment, decreasing by
217 24 hours after treatment, and completely resolved in all cases within 5 days of treatment. Martinez-
218 de-la-Casa et al[69] evaluated flare using the Kowa flare meter, and found significantly lower flare
219 readings after SLT than ALT. Damji and colleagues[68] reported more anterior chamber
220 inflammation in the first 1 hour after SLT than ALT. Nagar and colleagues[26] reported a 50% rate of
221 anterior chamber inflammation in eyes receiving 360 degrees SLT versus 0% in latanoprost-treated
222 eyes. A single case report of hyphema after SLT has also been reported[72]. The damage to the

cornea to due the close proximity of the cornea with the trabecular meshwork has been reported.[79-80]

None our patient had significant anterior segment inflammation.

2.Ocular Discomfort

Latina and colleagues[49] reported that 15% of eyes receiving SLT reported discomfort after the procedure. Martinez-de-la-Casa and colleagues [69] evaluated postoperative pain using a 10-point scale and found significantly lower pain scores after SLT compared with ALT during and immediately after treatment; these differences were gone by 24 hours post treatment. Nagar and colleagues[26] reported a 39% rate of discomfort in eyes undergoing 360 degrees SLT and a 0% rate in eyes receiving latanoprost. None of our patient had ocular discomfort following SLT immediate post op and on Day¹.

3.IOP Spikes

Latina and colleagues[49] reported IOP spikes of 5mm Hg or greater in 25% of SLT-treated eyes and IOP spikes of 8mm Hg or greater in 9% of treated eyes. All manifested within 2 hours after treatment, resolved with IOP-lowering medications within 24 hours, and none of eyes exhibited a persistent IOP elevation. Damji and coworkers[68] reported that 3.4% of ALT-treated eyes and

4.5% of SLT-treated eyes exhibited an IOP rise of 6mm Hg or greater within 1 hour after treatment. Nagar and colleagues[26] reported that 27% of eyes undergoing 360 degrees SLT manifested an IOP spike of 5mm Hg or

more (compared with no IOP spikes in latanoprost treated eyes). Lai and coworkers[70] reported that 10.3% of 360 degrees SLT-treated eyes manifested an IOP spike of 5mm Hg or greater. None of our patient had persistently raised IOP following SLT. As all our patient were on antiglaucoma therapy following SLT and continued on same medication following SLT. Thus taking care of IOP spike component also .

Table 1. Shows comparison of our study with different studies.

Study	Populat ion	Treatme nt	Baseline IOP (mm Hg)	Follow up	IOP reduction	Definition of success	Response Rate	Comments
Prese nt study	37 eyes of 33 patients of OAG	360 degree SLT	23.78±6 .38	1 year	4.04 ± 1.01 mmHg (17% of baseline IOP) .	IOP control without retreatme nt or without additional antiglauc oma or	60%	Response to SLT not affected by age , different diagnosis, number of topical medicatio

						surgery		n
Latina et al[49]	53 eyes	SLT nasal 180 degree	24.6	26 weeks	4.6 mm Hg	IOP reduction ≥ 3 mmHg	73 %	Similar IOP reduction in eyes with or without ALT
Lanzetta et al[54]	8 eyes	360 degree SLT	26.6 $\pm$ 7	6 weeks	10.6 $\pm$ 5.2	NA	NA	
Kajiya et al[55]	17 eyes of 10 patients	180 degree SLT	22.8	6 months	6.7 mmHg	NA	NA	
Chen et al[57]	2 groups of 32 patients	180 degree SLT	26.06	7 months	6.16(24 %)	IOP controlled without retreatment or trab at 7 months	59%	IOP reduction significantly related to trabecular pigmentation
Hodgson et al[65]	72 patients with OAG on MTMT	180 degree SLT	23.8 $\pm$ 4.88	12 months	5.8 mmHg(24.4%)	IOP reduction of >20% after 1 year	60%	IOP reduction significantly related to higher baseline IOP , but not to all other factors examined
Damji et al[68]	2 groups of 18 eyes with OAG	180 degree SLT	22.8 $\pm$ 3 mmHg	6 months	4.8 $\pm$ 3.4 mmHg			Similar IOP reduction by ALT and SLT
		180 degree	22.5 $\pm$ 3.		4.7 $\pm$ 3.3			

		ALT	6		mmHg			
Lai et al[70]	29 chinese patients with POAG or OHTN	360 degree SLT (fellow eye treated with medication	26.2±4.2	5 years (82.8% completed follow up)	8.6±6.7 mHg (32.1%)	IOP ≤21 mmHg without medication	72%	Similar IOP reduction by SLT and medication
						IOP ≤21mmHg on MTMT	83%	
Gracner [58]	10 patients of XFG	Inferior 180 degree SLT	23.6±5.7	12 ±5.5 months	6.0±3.3	IOP reduction ≥20% and no progression on VF or ON changes after 1 year	70%	Results not statistically significant between eyes with POAG and XFG
	10 patients of POAG		22,8±2.4	13.5±4.3 months	6.5±2.8			
Song et al[53]	94 patients with OAG	180 degree SLT	17.6	Mean 10.6 months	2.1	IOP reduction >3 mmHg	32%	Only significant predictor of failure was lower preoperative IOP
Francis et al[59]	66 patients with medical ly controll	180 degree SLT		12 months		Ability to decrease medication while maintaining target	87 % discontinued a mean of 2.0 medicati	

	ed POAG or XFG					IOP	ons at 6 months and 1.5 at 12 months	
--	----------------------	--	--	--	--	-----	--	--

248

249

Limitation

250 1. One of the limitations of our study was only 1 year follow-up time. The original purpose of
251 the present study was to evaluate efficacy of SLT in lowering IOP following SLT treatment, so a
252 longer follow-up is needed. Considering IOP, several studies have indicated that IOP remains stable
253 at 6 months⁴⁹ and 18 months⁶⁴.

254 2. The initial IOP spikes could have been missed due to the first post procedure visit at 24
255 hours. But all our patients were on antiglaucoma medications and it was continued after the
256 procedure.

257 3. There were predominant males in our study [28 males (31 eyes), 5 females(6 eyes)] , we
258 cannot comment conclusively whether efficacy of SLT is affected by sex.

259 4. We had predominantly POAG and less of other forms open angle glaucoma subgroups,
260 hence difference in efficacy in various subgroups cannot be commented conclusively.

SUMMARY AND CONCLUSIONS

262 1. In our study we included 37 eyes of 33 patients of open angle glaucoma with baseline IOP of
263 23.78 ± 6.39 mmHg. Post SLT mean IOP at 1 month was 17.38 ± 5.04 mmHg which was comparable
264 to IOP at 3 months (19.00 ± 5.04 mmHg) at 6 months it was 16.93 ± 4.03 mmHg(31.23% reduction)
265 and at 1 year it was 16.47 ± 4.04 mmHg (31.3% reduction). The IOP at 1 year was significantly lower
266 from baseline IOP (23.78 ± 6.39 mmHg).

267 2. We did 360 degree SLT of trabecular meshwork in single sitting . We have not given post
268 operatively any anti-inflammatory therapy. The patients continued to use prior antiglaucoma
269 medications.

270 3. Our results, though limited, seem to show that selective laser trabeculoplasty is effective as
271 a secondary/adjunctive treatment for lowering IOP in patients of open angle glaucoma not
272 adequately controlled with medical therapy in Indian eyes.

273 4. Our results, though limited, seem to show that SLT is a safe procedure . As none of our
274 patients had any significant side effects.

275 5. SLT has a good compliance.

276 6. Our results, though limited, seem to show that SLT can be tried in patients of JOAG also.
277 Although , long term success is questionable but still SLT seems like a promising therapy in such
278 cases. SLT is equally efficacious in different glaucoma subgroups of open angle glaucoma.

- 279 7. Our results, though limited, seem to show that efficacy of SLT is not affected by age,
- 280 8. Our results, though limited, seem to show that efficacy of SLT in lowering IOP is same in
- 281 males and females
- 282 9. Our results, though limited, seem to show that efficacy of SLT in IOP lowering is not affected
- 283 by number of topical antiglaucoma medications. In our study patients with maximum tolerated
- 284 medical therapy also responded to SLT similar to patients who were on single drug. So, SLT can be
- 285 used as an adjunct to medical therapy and also defer need of glaucoma filtration surgery.

286

287

REFERENCES

- 288 1. Girkin CA. Relationship between structure of optic nerve/nerve fiber layer and functional
- 289 measurements in glaucoma. *Current Opin Ophthalmol* 2004;15:96-101.
- 290 2. Robert N. Weinreb, MD et al, The Pathophysiology and Treatment of Glaucoma: A Review
- 291 *JAMA*. 2014 May 14; 311(18): 1901–1911, 2014
- 292 3. S. K. Gupta et al, Recent advances in pharmacotherapy of glaucoma, *Indian J Pharmacol*.
- 293 2008 Oct; 40(5): 197–208
- 294 4. Dawodu OA, Otakpor AN and Ukponmwan CU. Common psychiatric disorders in glaucoma
- 295 patients as seen at the University of Benin Teaching Hospital, Benin City, Nigeria. *JMBR: A Peer-*
- 296 *review. Journal of Biomedical Sciences* 2004;3(1):42-47.
- 297 5. Higginbotham EJ: Reaffirming the role of the laser in glaucoma management. *Arch*
- 298 *Ophthalmol* 117:1075--6, 1999.
- 299 6. Jampel HD: Initial treatment for open-angle glaucoma medical, laser, or surgical? *Laser*
- 300 *Trabeculoplasty is the treatment of choice for chronic open-angle glaucoma. Arch Ophthalmol*
- 301 116:240--1, 1998.
- 302 7. Olthoff CM, Schouten JS, van de Borne BW, Webers CA: Noncompliance with ocular
- 303 hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based
- 304 review, *Ophthalmology* 112:953--61, 2005.
- 305 8. Wise JB, Witter SL: Argon laser therapy for open-angle glaucoma, a pilot study. *Arch*
- 306 *Ophthalmology* 97:319--22, 1979.
- 307 9. Lee MD, Fechtner FR, Fiscella RG, et al: Emerging Perspectives on glaucoma: highlights of a
- 308 roundtable discussion. *Am J Ophthalmology* 130(Suppl):S1--S11, 2000.
- 309 10. Nordstrom BL, Friedman DS, Mozaffari E, et al: Persistence and adherence with topical
- 310 glaucoma therapy. *Am J Ophthalmol* 140:598--606, 2005.
- 311 11. Stewart WC, Konstas AG, Pfeiffer N: Patient and ophthalmologist attitudes concerning
- 312 compliance and dosing in glaucoma treatment. *J Ocul Pharmacol Ther* 20:461--9, 2004.

- 313 12. Jampel HD, Musch DC, Gillespie BW, et al: Perioperative complications of trabeculectomy in
314 the collaborative initial glaucoma treatment study (CIGTS). *Am J Ophthalmol* 140:16--22, 2005.
- 315 13. Busbee BG, Recchia FM, Kaiser R, et al: Bleb-associated endophthalmitis: clinical
316 characteristics and visual outcomes. *Ophthalmology* 111:1495--503, 2004.
- 317 14. Spurny RC, Lederer CM Jr: Krypton laser trabeculoplasty, a clinical report. *Arch Ophthalmol*
318 102:1626--8, 1984.
- 319 15. Guzey M, Arslan O, Tamcelik N, Satıcı A: Effects of frequency-doubled Nd:YAG laser
320 trabeculoplasty on diurnal intraocular pressure variations in primary open-angle glaucoma.
321 *Ophthalmologica* 213:214--8, 1999.
- 322 16. Nelson WL, Fraunfelder FT, Sills JM, et al: Adverse respiratory and cardiovascular events
323 attributed to timolol ophthalmic solution, 1978--1985. *Am J Ophthalmol* 102:606--11, 1986.
- 324 17. Osborne SA, Montgomery DM, Morris D, McKay IC: Alphagan allergy may increase the
325 propensity for multiple eye-drop allergy. *Eye* 19:129--37, 2005.
- 326 18. Broadway DC, Grierson I, O'Brien C, Hitchings RA: Adverse effects of topical antiglaucoma
327 medication. I. The conjunctival cell profile. *Arch Ophthalmol* 112:1437--45, 1994.
- 328 19. Noecker RJ, Herrygers LA, Anwaruddin R: Corneal and conjunctival changes caused by
329 commonly used glaucoma medications. *Cornea* 23:490--6, 2004.
- 330 20. AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS), 9. comparison of
331 glaucoma outcomes in black and white patients within treatment groups. *Am J Ophthalmol* 132:311--
332 20, 2001.
- 333 21. Ederer F, Gaasterland DA, Dally LG, et al: The Advanced Glaucoma Intervention Study (AGIS):
334 13. Comparison of treatment outcomes within race: 10-year results. *Ophthalmology* 111:651--64,
335 2004.
- 336 22. Reiss GR, Wilensky JT, Higginbotham EJ: Laser trabeculoplasty. *Surv Ophthalmol* 35:407--28,
337 1991.
- 338 23. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes
339 within race, seven-year results. *Ophthalmology* 105:1146--64, 1998.
- 340 24. The Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT) and glaucoma
341 laser trial follow-up study, seven-year results. *Am J Ophthalmol* 120:718--31, 1995.
- 342 25. The Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT), 2. Results of
343 argon laser trabeculoplasty versus topical medicines. *Ophthalmology* 97:1403--13, 1990.
- 344 26. Nagar M, Ogunyomade A, O'brart DP, et al: A randomised, prospective study comparing
345 selective laser trabeculoplasty with latanoprost for the control of intraocular pressure inocular
346 hypertension and open angle glaucoma. *Br J Ophthalmol* 89:1413--7, 2005.

- 347 27. Kramer TR, Noecker RJ: Comparison of the morphologic changes after selective laser
348 trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. *Ophthalmology* 108:773--9,
349 2001.
- 350 28. Melamed S, Pei J, Epstein DL: Short-term effect of argon laser trabeculoplasty in monkeys.
351 *Arch Ophthalmol* 103: 1546--52, 1985.
- 352 29. Rodrigues MM, Spaeth GL, Donohoo P: Electron microscopy of argon laser therapy in phakic
353 open-angle glaucoma. *Ophthalmology* 89:198--210, 1982.
- 354 30. Cvenkel B, Hvala A, Drnovsek-Olup B, Gale N: Acute ultrastructural changes of the trabecular
355 meshwork after selective laser trabeculoplasty and low power argon laser trabeculoplasty. *Lasers*
356 *Surg Med* 33:204--8, 2003.
- 357 31. Guzey M, Vural H, Satıcı A, Karadede S, Dogan Z: Increase of free oxygen radicals in aqueous
358 humour induced by selective Nd:YAG laser trabeculoplasty in the rabbit. *Eur J Ophthalmol* 11:47--52,
359 2001.
- 360 32. Roider J, Hillenkamp F, Flotte T, Birngruber R: Microphotocoagulation: selective effects of
361 repetitive short laser pulses. *Proc Natl Acad Sci USA* 90:8643--7, 1993.
- 362 33 Roider J, Michaud NA, Flotte TJ, Birngruber R: Response of the retinal pigment epithelium to
363 selective photocoagulation. *Arch Ophthalmol* 110:1786--92, 1992.
- 364 34. Roider J, Lindemann C, el-Hifnawi el-S, et al: Therapeutic range of repetitive nanosecond
365 laser exposures in selective RPE photocoagulation. *Graefes Arch Clin Exp Ophthalmol* 236:213--9,
366 1998.
- 367 35. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. *Ophthalmic*
368 *Surg.* 1995;26:234--236.
- 369 36. Kass MA, Gordon M, Morley RE Jr, et al. Compliance with topical timolol treatment. *Am J*
370 *Ophthalmol.* 1987;15:188--193.
- 371 37. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary
372 open-angle glaucoma suspects. *Am J Ophthalmol.* 2004;137(1 suppl):S13--S16.
- 373 38. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary
374 therapy? *Ophthalmology.* 2005;112:863--868.
- 375 39. Brandt JD, Wittmann JR, Katz LJ, et al. Conjunctival impression cytology in patients with
376 glaucoma using longterm topical medications. *Am J Ophthalmol.* 1991;112:297--301.
- 377 40. Bergea B, Bodin L, Svedbergh B. Impact of IOP regulation on visual fields in open angle
378 glaucoma. *Ophthalmology.* 1999;106: 997--1005.
- 379 41. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an
380 independent risk factor in patients with glaucoma. *J Glaucoma.* 2000;9:134--142.

- 381 42. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual
382 field progression in the Advanced Glaucoma Intervention Study. *Ophthalmology*. 2004;111:1627–
383 1635.
- 384 43. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and
385 latanoprost on intraocular pressure. *Am J Ophthalmol*. 2004;138:389–395.
- 386 44. Walters TR. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution,
387 or latanoprost: a 1-month, randomized, comparative clinical trial. *Surv Ophthalmol*. 2004;49(suppl
388 1):S26–S35.
- 389 45. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-
390 combination therapy versus monotherapy with timolol or brimonidine in patients with glaucoma or
391 ocular hypertension: a 12-month randomized trial. *Arch Ophthalmol*. 2006;124:1230–1238.
- 392 46. Greenidge KC, Spaeth GL, Fiol-Silva Z. Effect of argon laser trabeculoplasty on the
393 glaucomatous diurnal curve. *Ophthalmology*. 1983;90:800–804.
- 394 47. Elsas T, Junk H, Johnsen H. Diurnal intraocular pressure after successful primary laser
395 trabeculoplasty. *Am J Ophthalmol*. 1991;112:67–69.
- 396 48. Lee R, Hutnik CM. Projected cost comparison of selective laser trabeculoplasty versus
397 glaucoma medication in the Ontario Health Insurance Plan. *Can J Ophthalmol*. 2006;41: 449–456.
- 398 49. Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532-nm Nd:YAG laser trabeculoplasty
399 (selective laser trabeculoplasty): a multicenter, pilot, clinical study. *Ophthalmology*. 1998;105: 2082–
400 2090.
- 401 50. Almeida EDJ, Pinto LM, Fernandes RA et al (2011) Pattern of intraocular pressure reduction
402 following laser trabeculoplasty in open-angle glaucoma patients: comparison between selective
403 and nonselective treatment. *Clin Ophthalmol* 5:933–936.
- 404 51. McIlraith I, Strasfeld M, Colev G et al (2006) Selective laser trabeculoplasty as initial and
405 adjunctive treatment for open-angle glaucoma. *J Glaucoma* 15:124–130.
- 406 52. Realini T (2008) Selective laser trabeculoplasty: a review. *J Glaucoma* 17:497–502.
- 407 53. Song J, Lee PP, Epstein DL et al (2005) High failure rate associated with 180 degrees
408 selective laser trabeculoplasty. *J Glaucoma* 14:400–408.
- 409 54. Lanzetta P, Menchini U, Virgili G: Immediate intraocular pressure response to selective laser
410 trabeculoplasty. *Br J Ophthalmol* 83:29–32, 1999.
- 411 55. Kajiya S, Hayakawa K, Sawaguchi S: Clinical results of selective laser trabeculoplasty. *Jpn J*
412 *Ophthalmol* 44:574–5, 2000.
- 413 56. Cvenkel B: One-year follow-up of selective laser trabeculoplasty in open-angle glaucoma.
414 *Ophthalmologica* 218:20–5, 2004.

- 415 57. Chen E, Golchin S, Blomdahl S: A comparison between 90 degrees and 180 degrees selective
416 laser trabeculoplasty. *J Glaucoma* 13:62--5, 2004.
- 417 58. Gracner T: Intraocular pressure response of capsular glaucoma and primary open-angle
418 glaucoma to selective Nd:YAG laser trabeculoplasty: a prospective, comparative clinical trial. *Eur J*
419 *Ophthalmol* 12:287--92, 2002.
- 420 59. Francis BA, Ianchulev T, Schofield JK, Minckler DS: Selective laser trabeculoplasty as a
421 replacement for medical therapy in open-angle glaucoma. *Am J Ophthalmol* 140: 524--5, 2005.
- 422 60. Johnson PB, Katz LJ, Rhee DJ: Selective laser trabeculoplasty: predictive value of early
423 intraocular pressure measurements for success at 3 months. *Br J Ophthalmol* 90:741--3, 2006.
- 424 61. Barkana Y, Belkin M (2007) Selective laser trabecu--loplasty. *Surv Ophthalmol* 52:634--654.
- 425 62. C. Hirn, S.A. Zweifel, M. Töteberg Harms, J. Funk, Efficacy of selective laser trabeculoplasty in
426 patients with insufficient intraocular pressure under maximal therapy, *Ophthalmology* 2012 •
427 109:683-690.
- 428 63. Rachmiel R, Trope GE, Chipman ML et al (2006) Laser trabeculoplasty trends with the
429 introduction of new medical treatments and selective laser tra--beculoplasty. *J Glaucoma* 15:306--
430 309.
- 431 64. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary
432 treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. *Arch Ophthalmol*.
433 2003;121(7): 957--960.
- 434 65. Hodge WG, Damji KF, Rock W, Buhrmann R, Bovell AM, Pan Y. Baseline IOP predicts selective
435 laser trabeculoplasty success at 1 year post treatment: results from a randomised clinical trial, *Br J*
436 *Ophthalmol*, 2005, September, 89,1157-1160.
- 437
- 438 66. Behrooz Koucheiki, Hashemi H., Selective Laser Trabeculoplasty in the Treatment of Open-angle
439 Glaucoma, *J Glaucoma* 2012;21:65--70.
- 440 67. Almeida ED Jr, Pinto LM, Fernandes RA, Prata TS. Pattern of intraocular pressure reduction
441 following laser trabeculoplasty in open-angle glaucoma patients: comparison between selective and
442 nonselective treatment, *Clinical Ophthalmology* 2011;5 933--936.
- 443
- 444 68. Damji KF, Shah KC, Rock WJ, et al: Selective laser trabeculoplasty v argon laser trabeculoplasty: a
445 prospective randomised clinical trial. *Br J Ophthalmol* 83:718--22, 1999.
- 446 69. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, et al: Selective vs argon laser trabeculoplasty:
447 hypotensive efficacy, anterior chamber inflammation, and postoperative pain. *Eye* 18:498--502,
448 2004.
- 449 70. Lai JS, Chua JK, Tham CC, Lam DS: Five-year follow up of selective laser trabeculoplasty in Chinese
450 eyes. *Clin Experiment Ophthalmol* 32:368--72, 2004.

- 451 71. Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G ,Selective Laser
452 Trabeculoplasty Versus Medical Therapy as Initial Treatment of Glaucoma: A Prospective,
453 Randomized Trial, J Glaucoma 2012;21:460–468.
- 454 72. Shihadeh WA, Ritch R, Liebmann JM. Hyphema occurring during selective laser trabeculoplasty.
455 Ophthalmic Surg Lasers Imaging. 2006;37:432–433.
- 456 73. Stein, Joshua D; Challa, Pratap, Mechanisms of action and efficacy of argon laser trabeculoplasty
457 and selective laser trabeculoplasty, Current Opinion in Ophthalmology: March 2007 - Volume 18 -
458 Issue 2 - p 140-145.
- 459 74. Yaniv Barkana, Michael Belkin (Alvadro JA, International Glaucoma Symposium, 2003)
460 Diagnostic and surgical technique, Survey of ophthalmology Volume 52, 634-654, Nov –Dec 2007.
- 461 75. Lee JWY, Shum JW, Chan JCH, Lai JSM. Two-year clinical results after selective laser
462 trabeculoplasty for normal tension glaucoma. Medicine (Baltimore). 2015; 94(24): e984. DOI:
463 10.1097/MD.0000000000000984.
- 464 76. Lee JWY, Ho WL, Chan JCH, Lai JSM. Efficacy of selective laser trabeculoplasty for normal
465 tension glaucoma: 1 year results. BMC Ophthalmology. 2015; 15(1). DOI: 10.1186/1471-2415-15-1.
- 466 77. Lee JWY, Liu CCL, Chan JCH, Lai JSM. Predictors of success in selective laser trabeculoplasty
467 for normal tension glaucoma. Medicine (Baltimore). 2014; 93(28):e236. DOI:
468 10.1097/MD.0000000000000236.
- 469 78. Lee JWY, Liu CCL, Chan JCH, Lai JSM. Predictors of success in selective laser trabeculoplasty for
470 Chinese open-angle glaucoma. Journal of Glaucoma. 2014; 23(5):321-5. DOI:
471 10.1097/IJG.0000000000000049
- 472 79. Lee JW, Chan JC, Chang RT, Singh K, Liu CC, Gangwani R, Wong MO, Lai JS. Corneal changes after
473 a single session of selective laser trabeculoplasty for open-angle glaucoma. Eye (Lond). 2014;
474 28(1):47-52. DOI: 10.1038/eye.2013.231.
- 475 80. Wong MOM, Lee JWY, Choy BNK, Chan JCH, Lai JSM. Systematic review and meta-analysis on
476 the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Survey of Ophthalmology.
477 2015;60(1):36-50. DOI: 10.1016/j.survophthal.2014.06.006.
- 478